A
Acousia Therapeutics
Develops therapy for hearing loss
About Acousia Therapeutics
Acousia Therapeutics GmbH is a clinical-stage biotechnology firm, established in 2012, operating from Tübingen, Germany. The company was co-founded by Professor Dr. Hubert Löwenheim of the University of Tuebingen, EMC Microcollections, and the Boehringer Ingelheim Venture Fund (BIVF). Löwenheim, a recognized expert in otolaryngology, provides a deep scientific and clinical foundation for the company's mission, stemming from his extensive research in hearing loss. Acousia is focused on a significant and largely unaddressed market: therapeutic treatments for sensorineural hearing loss (SNHL), which accounts for over 90% of all hearing loss cases.
The company's core business is the discovery and development of small-molecule drugs designed to protect and restore auditory function. This positions Acousia as an alternative and potential complement to existing hearing aids and cochlear implants, which do not restore natural hearing. The business model centers on advancing its drug candidates through clinical trials to eventually secure regulatory approval and commercialization. The primary clients are patients experiencing hearing loss from a variety of causes, including ototoxic drugs, age-related decline, and noise exposure. Acousia has cultivated a strong investor consortium including BIVF, LBBW Venture Capital, Creathor Ventures, Bregua Corporation, KfW, and Esperante Ventures to fund its capital-intensive research and development.
Acousia's lead drug candidate is ACOU085 (bimokalner), a small-molecule Kv7.4 potassium channel agonist. This drug has a dual mode of action: it provides acute enhancement of hearing function while also delivering long-term protection to the sensory outer hair cells (OHCs) in the inner ear. ACOU085 is administered via a transtympanic injection of a proprietary slow-release gel, designed to ensure sustained target engagement in the cochlea. A key focus for ACOU085 is preventing ototoxicity—irreversible hearing damage—a common side effect for cancer patients undergoing cisplatin-based chemotherapy. The company is conducting the PROHEAR study, a Phase 2a clinical trial, to evaluate the drug's efficacy in testicular cancer patients receiving this chemotherapy. The trial, which began enrolling patients in late 2023, uses a split-body design where each patient serves as their own control, receiving the drug in one ear and a placebo in the other. The study reached 50% enrollment as of April 2025 and aims for completion by the end of the second half of 2025.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Hearing, Spinout, Biotech and Pharma, DT and LS, science-based
- Technology
- Hardware, Connected Device
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jan 2024 | $0 | — | Esperante Ventures | ↗ |
| SERIES B✓Equity / VC | May 2018 | $11M | $44M | LBBW Venture Capital · Bregua Corporation · KfW · Creathor Ventures | ↗ |
Growth signals
Latest recorded traffic for Acousia Therapeutics is 1.9K monthly website visits, up 46.2% over the last three months. Acousia Therapeutics's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Acousia Therapeutics in the Tübingen ecosystem
The Acousia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Boehringer Ingelheim Venture Fund
KfW
Axxam
Creathor Ventures
LBBW Venture Capital- BCBregua Corporation
Series B and later1 investor entered at this stage
Esperante Ventures
Other known investors1 additional known investor
University of Tübingen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acousia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acousia Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









